Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Claudia Perez-Tamayo

Therapeutic Radiology Emporia, KS Medical Doctor

NPI 1366403537 CMS profile 334244

1401 W 12Th Ave, Emporia, KS 66801

Open in the dashboard

General payments

$4,012

180 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Claudia Perez-Tamayo of Emporia, KS is reported in the CMS Open Payments database as having received $4,012 across 180 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Therapeutic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,754 52
2024 General $922 50
2023 General $548 29
2022 General $248 14
2021 General $152 11
2020 General $72 5
2019 General $316 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Claudia Perez-Tamayo
  • Therapeutic Radiology median
  • Middle half of Therapeutic Radiology
  • National median

In program year 2025, general payments to Claudia Perez-Tamayo were reported at $1,754. Among 82 Therapeutic Radiology profiles paid that year, the median was $179 and the middle half received between $54 and $602.

Show as a table
Year Claudia Perez-Tamayo Therapeutic Radiology median Middle half National median
2019 $316 $108 $31–$339 $163
2020 $72 $48 $28–$197 $114
2021 $152 $72 $23–$391 $132
2022 $248 $77 $31–$399 $149
2023 $548 $148 $55–$613 $160
2024 $922 $172 $45–$795 $164
2025 $1,754 $179 $54–$602 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $368 8 payments
  2. Novartis Pharmaceuticals Corporation $334 19 payments
  3. Janssen Biotech, Inc. $237 13 payments
  4. Merck Sharp & Dohme Corporation $212 11 payments
  5. Regeneron Healthcare Solutions, Inc. $202 5 payments
  6. Novocure Inc. $147 2 payments
  7. Pharmacosmos Therapeutics Inc. $147 2 payments
  8. Daiichi Sankyo Inc. $144 6 payments
  9. BeOne Medicines USA, Inc. $128 3 payments
  10. Genzyme Corporation $126 7 payments
  11. Other $1,968 104 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,012 180 payments
Products named General payments · program years 2019–2025
  1. PLUVICTO $236 12 payments
  2. LIBTAYO $217 6 payments
  3. KEYTRUDA $212 11 payments
  4. OPTUNE LUA (NOVOTTF-200T) $147 2 payments
  5. ENHERTU $132 5 payments
  6. MONOFERRIC $125 1 payment
  7. IMDELLTRA (AMG757) $122 1 payment
  8. BRUKINSA $99 2 payments
  9. ZEPZELCA $92 4 payments
  10. POLIVY $86 4 payments
  11. Other $2,785 155 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

35

Median for Radiation Oncology: 65

Drug cost

$1,495

Median for Radiation Oncology: $978

Branded share of claims

0%

Median for Radiation Oncology: 7.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Betamethasone Dipropionate Generic 24 $1,255
Fluconazole Generic 11 $240

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,680 Part D prescribers listed as Radiation Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 108 billing codes

Paid by Medicare

$1,594,297

Of which drugs: $41,772

Medicare patients

346

Average age 75

Services billed

18,579

161 women, 185 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 68%
Arthritis 44%
COPD 35%
Ischemic heart disease 34%
Diabetes 29%
Chronic kidney disease 28%
Atrial fibrillation 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 19 2,000 $215

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PLUVICTO
  • Novartis Pharmaceuticals Corporation $116
$116 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $67
$67 — —
Orserdu
  • Stemline Therapeutics Inc. $62
$62 — —
ENHERTU
  • Daiichi Sankyo Inc. $57
$57 — —
OJJAARA
  • GlaxoSmithKline, LLC. $41
$41 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

180 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record